NO20075113L - Proteinkinaseinhibitorer - Google Patents

Proteinkinaseinhibitorer

Info

Publication number
NO20075113L
NO20075113L NO20075113A NO20075113A NO20075113L NO 20075113 L NO20075113 L NO 20075113L NO 20075113 A NO20075113 A NO 20075113A NO 20075113 A NO20075113 A NO 20075113A NO 20075113 L NO20075113 L NO 20075113L
Authority
NO
Norway
Prior art keywords
protein kinase
kinase inhibitors
useful
present
prodrugs
Prior art date
Application number
NO20075113A
Other languages
English (en)
Norwegian (no)
Inventor
David J Bearss
Hariprasad Vankayalapati
Cory L Grand
Original Assignee
Supergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supergen Inc filed Critical Supergen Inc
Publication of NO20075113L publication Critical patent/NO20075113L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20075113A 2005-04-28 2007-10-09 Proteinkinaseinhibitorer NO20075113L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67646705P 2005-04-28 2005-04-28
PCT/US2006/016423 WO2006116733A2 (fr) 2005-04-28 2006-04-28 Inhibiteurs des proteines kinases

Publications (1)

Publication Number Publication Date
NO20075113L true NO20075113L (no) 2007-11-23

Family

ID=37029567

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075113A NO20075113L (no) 2005-04-28 2007-10-09 Proteinkinaseinhibitorer

Country Status (13)

Country Link
US (1) US20090029982A1 (fr)
EP (1) EP1888588A2 (fr)
JP (1) JP2008539277A (fr)
KR (1) KR20080020602A (fr)
CN (1) CN101189239A (fr)
AU (1) AU2006239236A1 (fr)
BR (1) BRPI0609956A2 (fr)
CA (1) CA2604284A1 (fr)
IL (1) IL186744A0 (fr)
MX (1) MX2007013624A (fr)
NO (1) NO20075113L (fr)
WO (1) WO2006116733A2 (fr)
ZA (1) ZA200709269B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070149506A1 (en) 2005-09-22 2007-06-28 Arvanitis Argyrios G Azepine inhibitors of Janus kinases
WO2008079965A1 (fr) 2006-12-22 2008-07-03 Incyte Corporation Hétérocycles substitués servant d'inhibiteurs de janus kinases
JP2010523712A (ja) 2007-04-13 2010-07-15 スーパージェン， インコーポレイテッド 癌または過剰増殖の治療に有用なａｘｌキナーゼ阻害剤
EP2170886A1 (fr) * 2007-07-02 2010-04-07 Cancer Research Technology Limited 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, et 9h-1,3,6,9-tétraaza-fluorènes en tant qu'inhibiteurs de la fonction kinase chk1
CN103396409B (zh) * 2007-07-05 2015-03-11 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
FR2933983B1 (fr) * 2008-07-15 2010-08-27 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US10699235B2 (en) * 2009-05-05 2020-06-30 Oracle America, Inc. System, method and computer readable medium for placing advertisements into web pages
CN103562208B (zh) 2011-03-15 2016-08-31 默沙东公司 三环促旋酶抑制剂
WO2013013188A1 (fr) 2011-07-21 2013-01-24 Tolero Pharmaceuticals, Inc. Inhibiteurs de protéine kinase hétérocycliques
CN104105696B (zh) 2011-11-09 2017-11-14 癌症研究技术有限公司 5‑(吡啶‑2‑基‑氨基)‑吡嗪‑2‑腈化合物及其治疗用途
AU2013212457B2 (en) 2012-01-27 2017-02-16 Universite De Montreal Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
MX358819B (es) 2012-05-15 2018-09-05 Cancer Research Tech Ltd 5-[[4-[[morfolin-2-il]metilamino]-5-(trifluorometil)-2-piridil]am ino]pirazina-2-carbonitrilo y usos terapeuticos del mismo.
CN104804002B (zh) * 2015-04-08 2017-02-01 河南师范大学 一种9H‑嘧啶并[4,5‑b]吲哚类化合物的合成方法
EP3303570B1 (fr) 2015-06-05 2021-01-20 Héma-Québec Méthodes pour cultiver et/ou différencier des cellules souches hématopoïétiques en progéniteurs, et utilisations correspondantes
CN105037374B (zh) * 2015-07-14 2017-04-12 吉林大学 N‑丁基‑9H‑嘧啶并[4,5‑b]吲哚‑2‑甲酰胺的制备方法
WO2017205977A1 (fr) 2016-06-01 2017-12-07 Universite De Montreal Sélection de cellules souches hématopoïétiques humaines à l'aide de l'epcr
AU2019247498A1 (en) 2018-04-05 2020-11-26 Sumitomo Pharma Oncology, Inc. AXL kinase inhibitors and use of the same
MX2021009371A (es) 2019-02-12 2021-09-10 Sumitomo Pharma Oncology Inc Formulaciones que comprenden inhibidores de proteina cinasa heterociclicos.
MX2022007278A (es) * 2019-12-18 2022-09-19 Univ Montreal Moduladores del adaptador kbtbd4 de cullin 3 como compuestos anti-cáncer.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1169795C (zh) * 1996-10-01 2004-10-06 协和发酵工业株式会社 环胺取代的含氮杂环化合物及其组合物
RU2002110461A (ru) * 1999-09-21 2004-03-10 Астразенека Аб (Se) Производные хиназолина и их применение в качестве фармацевтических веществ
EP1315715B1 (fr) * 2000-08-18 2008-07-23 Millennium Pharmaceuticals, Inc. Derives de quinazoline utilises comme inhibiteurs de kinase
US7115741B2 (en) * 2001-09-06 2006-10-03 Levy Daniel E 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds
MXPA04004019A (es) * 2001-10-31 2004-07-08 Bayer Healthcare Ag Derivados de pirimido?4,5-b?indol.
GB0313766D0 (en) * 2003-06-13 2003-07-23 Xenova Ltd Pharmaceutical compounds
SI1678166T1 (sl) * 2003-10-14 2009-10-31 Univ Arizona State Inhibitorji proteinske kinaze

Also Published As

Publication number Publication date
MX2007013624A (es) 2008-02-12
CA2604284A1 (fr) 2006-11-02
AU2006239236A1 (en) 2006-11-02
US20090029982A1 (en) 2009-01-29
IL186744A0 (en) 2008-02-09
KR20080020602A (ko) 2008-03-05
CN101189239A (zh) 2008-05-28
BRPI0609956A2 (pt) 2010-05-18
WO2006116733A3 (fr) 2006-12-14
ZA200709269B (en) 2009-01-28
JP2008539277A (ja) 2008-11-13
WO2006116733A2 (fr) 2006-11-02
EP1888588A2 (fr) 2008-02-20

Similar Documents

Publication Publication Date Title
NO20075113L (no) Proteinkinaseinhibitorer
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
NO20082643L (no) Isokinolinaminopyrazolderivater, deres fremstilling og anvendelse som farmasoytiske midler for behandling av kreft
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
DK1791830T3 (da) Diaminotriazol-forbindelser der er nyttige som protein-kinase-inhibitorer
NO20076502L (no) Pyrrolopyridiner nyttige som inhibitorer av proteinkinase
NO20082496L (no) Pyrazinderivater
NO20081569L (no) Administrasjon av dipeptidylpeptildaseinhibitorer
NO20083267L (no) Azaindole inhibitorer av aurora kinaser
ATE456565T1 (de) Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren
NO20082088L (no) Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer
SG170828A1 (en) Deazapurines useful as inhibitors of janus kinases
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
WO2009155121A3 (fr) Inhibiteurs de la pi3 kinase
ECSP055640A (es) Composiciones de pirazol útiles como inhibidores de gsk-3
NO20070655L (no) 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft
TN2009000128A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
NO20085099L (no) Puritonderivativer som HM74A agonister
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
NO20084747L (no) Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application